Antifungal agents and liver toxicity: a complex interaction
Authors:
- 23 June 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 14 (8) , 765-776
Abstract
The number of antifungal agents has sharply increased in recent decades. Antifungals differ in their spectrum of activity, pharmacokinetic/pharmacodynamic properties, dosing, safety-profiles and costs. Risk of developing antifungal associated hepatotoxicity is multifactorial and is influenced by pre-existing liver disease, chemical properties of the drug, patient demographics, comorbidities, drug-drug interactions, environmental and genetic factors. Antifungal related liver injury typically manifests as elevations in serum aminotransferase levels, although the clinical significance of these biochemical alterations is not always clear. Incidence rates of hepatotoxicity induced by antifungal therapy range widely, occurring most frequently in patients treated with azole antifungals for documented fungal infections. This review provides an update regarding the hepatotoxicity profiles of the modern systemic antifungals used in treatment of invasive fungal infections. Expert commentary: Understanding the likelihood and pattern of hepatotoxicity for all suspected drugs can aid the clinician in early detection of liver injury allowing for intervention and potential mitigation of liver damage. Therapeutic drug monitoring is emerging as a potential tool to assess risk for hepatotoxicity.Keywords
This publication has 106 references indexed in Scilit:
- Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting ConcentrationAntimicrobial Agents and Chemotherapy, 2012
- Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug MonitoringAntimicrobial Agents and Chemotherapy, 2012
- Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug MonitoringAntimicrobial Agents and Chemotherapy, 2012
- Systematic Review and Meta-Analysis of the Tolerability and Hepatotoxicity of Antifungals in Empirical and Definitive Therapy for Invasive Fungal InfectionAntimicrobial Agents and Chemotherapy, 2010
- Effect of Varying Amounts of a Liquid Nutritional Supplement on the Pharmacokinetics of Posaconazole in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2009
- Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557Antimicrobial Agents and Chemotherapy, 2009
- Lack of Allergic Cross-Reactivity between Fluconazole and VoriconazoleAntimicrobial Agents and Chemotherapy, 2009
- Oral versus Intravenous Flucytosine in Patients with Human Immunodeficiency Virus-Associated Cryptococcal MeningitisAntimicrobial Agents and Chemotherapy, 2007
- Risk/benefit ratio of modern antifungal therapy: Focus on hepatic reactionsJournal of the American Academy of Dermatology, 1993
- FluconazoleDrugs, 1990